文献速递神经肌肉病神经免疫

Rozanolixizumab治疗中重度全身型肌无力的2期随机对照试验

Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.
PubMed 文献 · Neurology · 2020-11-20

这项2a期随机双盲安慰剂对照试验纳入43例全身型肌无力患者,评估皮下注射rozanolixizumab的疗效与安全性。主要终点QMG评分变化未达统计学显著,但MG-ADL和MGC评分有改善趋势,最常见不良事件为头痛,总体耐受良好。

要点

  • rozanolixizumab 7 mg/kg每周皮下注射未显著改善QMG评分。
  • MG-ADL和MGC评分显示改善趋势,支持临床获益可能。
  • 最常见不良事件为头痛,rozanolixizumab组57% vs 安慰剂组14%。

核心结论

  • QMG评分变化未达统计学显著,但整体数据提示rozanolixizumab可能对全身型肌无力患者有临床获益且耐受良好。

研究设计与样本

  • 2a期随机双盲安慰剂对照多中心试验(NCT03052751),43例患者随机分配至rozanolixizumab 7 mg/kg组(21例)或安慰剂组(22例)。
  • 第1期(第1-29天)每周一次皮下注射rozanolixizumab 7 mg/kg或安慰剂,共3次;第2期(第29-43天)重新随机分配至rozanolixizumab 7 mg/kg或4 mg/kg,每周一次皮下注射共3次,随后观察至第99天。

主要发现

  • 第29天QMG评分最小二乘均值变化:rozanolixizumab组-1.8 vs 安慰剂组-1.2,差异-0.7(95%置信上限0.8),p=0.221,未达统计学显著。
  • 第29天MG-ADL评分最小二乘均值变化:rozanolixizumab组-1.8 vs 安慰剂组-0.4,差异-1.4(95%置信上限-0.4)。
  • 第29天MGC评分最小二乘均值变化:rozanolixizumab组-3.1 vs 安慰剂组-1.2,差异-1.8(95%置信上限0.4)。
  • 第2期rozanolixizumab 7 mg/kg组疗效指标持续改善。
  • 第1期最常见不良事件为头痛,rozanolixizumab组发生率57%,安慰剂组14%。

关键数值与推荐

  • 主要终点为基线至第29天QMG评分变化,未达统计学显著(p=0.221)。
  • 次要终点包括基线至第29天MG-ADL和MGC评分变化及安全性。

临床怎么用

  • rozanolixizumab可能为全身型肌无力患者提供临床获益且耐受良好,但主要终点未达显著,需3期试验进一步验证(NCT03971422)。

局限性

  • 本研究为2a期试验,样本量较小(43例),主要终点未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To explore the clinical efficacy and safety of subcutaneous (SC) rozanolixizumab, an anti-neonatal Fc receptor humanized monoclonal antibody, in patients with generalized myasthenia gravis (gMG). METHODS: In this phase 2a, randomized, double-blind, placebo-controlled, 2-period, multicenter trial (NCT03052751), patients were randomized (1:1) in period 1 (days 1-29) to 3 once-weekly (Q1W) SC infusions of rozanolixizumab 7 mg/kg or placebo. In period 2 (days 29-43), patients were re-randomized to either rozanolixizumab 7 mg/kg or 4 mg/kg (3 Q1W SC infusions), followed by an observation period (days 44-99). Primary endpoint was change from baseline to day 29 in Quantitative Myasthenia Gravis (QMG) score. Secondary endpoints were change from baseline to day 29 in MG-Activities of Daily Living (MG-ADL) and MG-Composite (MGC) scores and safety. RESULTS: Forty-three patients were randomized (rozanolixizumab 21, placebo 22 [period 1]). Least squares (LS) mean change from baseline to day 29 for rozanolixizumab vs placebo was as follows: QMG (LS mean -1.8 vs -1.2, difference -0.7, 95% upper confidence limit [UCL] 0.8; p = 0.221; not statistically significant), MG-ADL (LS mean -1.8 vs -0.4, difference -1.4, 95% UCL -0.4), and MGC (LS mean -3.1 vs -1.2, difference -1.8, 95% UCL 0.4) scores. Efficacy measures continued to improve with rozanolixizumab 7 mg/kg in period 2. The most common adverse event in period 1 was headache (rozanolixizumab 57%, placebo 14%). CONCLUSION: Whereas change from baseline in QMG was not statistically significant, the data overall suggest rozanolixizumab may provide clinical benefit in patients with gMG and was generally well tolerated. Phase 3 evaluation is ongoing (NCT03971422). CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with gMG, rozanolixizumab is well-tolerated, but did not significantly improve QMG score.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bril V, Benatar M, Andersen H, et al. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2020. PMID: 33219142. doi:10.1212/WNL.0000000000011108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。